18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) plus nivolumab (NIVO) in stage III melanoma

Rozeman, EA (author)

Menzies, AM (author)

Krijgsman, O (author)

show more...

Hoefsmit, EP (author)

van de Wiel, BA (author)

Sikorska, K (author)

Van, TM (author)

Eriksson, H (author)

Karolinska Institutet

Bierman, C (author)

Gonzalez, M (author)

Shannon, K (author)

Broeks, A (author)

Kerkhoven, R (author)

Spillane, AJ (author)

Saw, RP (author)

van Akkooi, ACJ (author)

Scolyer, RA (author)

Hansson, J (author)

Long, GV (author)

Blank, CU (author)

show less...

 (creator_code:org_t)

2019

2019

English.

In: ANNALS OF ONCOLOGY. - 0923-7534. ; 30

Related links:

http://kipublication...

• Conference paper (other academic/artistic)